HC Wainwright Has Optimistic Opinion of AUTL FY2027 Earnings

Posted by Geri Gentry on Nov 13th, 2026

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Free Report) – HC Wainwright raised their FY2027 EPS estimates for shares of Autolus Therapeutics in a research report issued on Wednesday, November 11th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($0.69) per share for the year, up from their previous estimate of ($0.74). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ FY2028 earnings at ($0.81) EPS, FY2029 earnings at ($0.69) EPS and FY2030 earnings at ($0.22) EPS.

A number of other equities research analysts have also recently weighed in on AUTL. Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Weiss Ratings downgraded shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 3rd. Finally, UBS Group reaffirmed a “buy” rating on shares of Autolus Therapeutics in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Autolus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Get Our Latest Stock Report on Autolus Therapeutics

Autolus Therapeutics Trading Down 3.6%

NASDAQ AUTL opened at $1.19 on Friday. The company has a debt-to-equity ratio of 5.25, a current ratio of 3.72 and a quick ratio of 4.40. The firm’s fifty day moving average price is $1.72 and its 200 day moving average price is $1.66. The company has a market capitalization of $316.94 million, a price-to-earnings ratio of -1.23 and a beta of 2.32. Autolus Therapeutics has a 12 month low of $1.12 and a 12 month high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). Autolus Therapeutics had a negative net margin of 186.37% and a negative return on equity of 263.25%. The business had revenue of $41.24 million during the quarter, compared to analysts’ expectations of $39.54 million. During the same quarter in the prior year, the business posted ($0.30) EPS.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AUTL. Private Advisor Group LLC acquired a new stake in shares of Autolus Therapeutics in the third quarter valued at approximately $28,000. GAMMA Investing LLC grew its position in shares of Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after acquiring an additional 8,309 shares during the last quarter. Vise Technologies Inc. acquired a new position in shares of Autolus Therapeutics in the 3rd quarter valued at $35,000. QRG Capital Management Inc. increased its holdings in shares of Autolus Therapeutics by 67.7% in the 2nd quarter. QRG Capital Management Inc. now owns 18,325 shares of the company’s stock valued at $29,000 after acquiring an additional 7,400 shares during the period. Finally, Waverly Advisors LLC acquired a new position in shares of Autolus Therapeutics in the 1st quarter valued at $37,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient’s T cells to recognize and attack specific cancer cells, using the company’s proprietary cell-engineering technology. The company’s lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.